• Molecular NameMethdilazine
  • SynonymMD; Methdilazine Hcl; Methdilazine hydrochloride; Methdilazine Monohydrochloride; Methdilazinum [INN-Latin]; Methilazine hydrochloride; Methodilazine; Metodilazina [INN-Spanish]
  • Weight296.438
  • Drugbank_IDDB00902
  • ACS_NO1982-37-2
  • Show 2D model
  • LogP (experiment)5.23
  • LogP (predicted, AB/LogP v2.0)4.57
  • pka7.5
  • LogD (pH=7, predicted)2.01
  • Solubility (experiment)0.000348 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-2.21
  • LogSw (predicted, AB/LogsW2.0)0.01
  • Sw (mg/ml) (predicted, ACD/Labs)0.01
  • No.of HBond Donors0
  • No.of HBond Acceptors2
  • No.of Rotatable Bonds2
  • TPSA31.78
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn antihistamine.
  • Absorption_valueN/A
  • Absorption (description)Well absorbed in the digestive tract.
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmN/A
  • Half lifeN/A
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySymptoms of overdose include clumsiness or unsteadiness, convulsions, drowsiness, dryness of mouth, nose, or throat, feeling faint, flushing or redness of face, hallucinations, muscle spasms (especially of neck and back), restlessness, shortness of breath or troubled breathing, shuffling walk, tic-like movements of head and face, trembling and shaking of hands, and trouble in sleeping.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A